Morningstar6d
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
T‑cell lymphomas, which often arise in extranodal lymphoid tissues, are highly aggressive and generally exhibit a poorer prognosis than their B‑cell counterparts with limited treatment options.
Hosted on MSN1mon
What Immunohistochemistry (IHC) Can Tell You
These markers often start with the letters CD. For instance, B-cell markers (CD20 and CD79a), T-cell markers (CD3 and CD5), and other markers like CD23, bcl-2, CD10, cyclinD1, CD15, CD30 ...
Nature5y
Balancing B-cell subsets in EAE
Rituximab, a CD20-specific monoclonal antibody that depletes B cells, has shown promising results in patients with relapsing-remitting multiple sclerosis. Studies of experimental autoimmune ...
Morningstar1mon
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
MB-105 is a first-in-class autologous CD5-targeted CAR-T cell therapy in development for CD5-positive hematologic malignancies, including T-cell lymphoma (TCL), T-cell acute lymphoblastic leukemia ...
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first ...
Finanznachrichten5d
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T-Cell Lymphoma CD5 CAR-NK Therapy
T-cell lymphomas, which often arise in extranodal lymphoid tissues, are highly aggressive and generally exhibit a poorer prognosis than their B-cell counterparts ... target the CD5 marker-which ...
Medindia5d
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T-Cell Lymphoma CD5 CAR-NK Therapy
YONGIN, South Korea, March 12, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for ...